Literature DB >> 11241790

Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18).

D E Horsman1, J M Connors, T Pantzar, R D Gascoyne.   

Abstract

Follicular lymphoma is characterized by the t(14;18) in up to 85% of cases. Almost all cases display evidence of secondary chromosomal alterations at initial diagnosis. The influence of recurrent secondary changes on disease progression has not been fully determined. The purpose of this study was to define the full spectrum of recurrent karyotypic events present at diagnosis in a large cohort of cases and to evaluate the sequence of cytogenetic evolution in relation to morphologic progression. A total of 165 cases of follicular lymphoma with t(14;18) were ascertained for which complete clinical information, histopathology, immunophenotype, and karyotype were available. One hundred sixty cases showed secondary alterations with an average of 7.9 additional changes per case. Recurrent alterations seen at the 10% or greater level included +X, +1q21-q44, +7, +12q, +18q, del(1)(p36), del(6q), del(10)(q22-q24), the development of polyploidy and sidelines, and the presence of extra marker chromosomes and chromosomal additions. Changes that correlated with morphologic progression included del(1)(p36), del(6q), del(10)(q22-q24), +7, the total number of abnormalities, the number of markers and additions, and the presence of polyploidy. The most frequent second event arising after the t(14;18) was duplication of the der(18)t(14;18). This study demonstrates that the number and type of secondary chromosomal alterations in follicular lymphoma is highly variable between cases, but that a relatively small number of changes are seen repeatedly in different combinations. A consistent pattern of cytogenetic evolution could not be identified. Potentially significant gene duplications or amplifications may be disguised within marker chromosomes and additions. Additional cytogenetic investigation is required to decipher the karyotypic complexity associated with the progression of follicular lymphoma. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11241790     DOI: 10.1002/gcc.1103

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

Review 1.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.

Authors:  James R Cerhan; Sophia Wang; Matthew J Maurer; Stephen M Ansell; Susan M Geyer; Wendy Cozen; Lindsay M Morton; Scott Davis; Richard K Severson; Nathaniel Rothman; Charles F Lynch; Sholom Wacholder; Stephen J Chanock; Thomas M Habermann; Patricia Hartge
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

3.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Authors:  Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2009-03-23       Impact factor: 22.113

4.  Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.

Authors:  Derville O'Shea; Ciarán O'Riain; Manu Gupta; Rachel Waters; Youwen Yang; David Wrench; John Gribben; Andreas Rosenwald; German Ott; Lisa M Rimsza; Harald Holte; Jean-Baptiste Cazier; Nathalie A Johnson; Elias Campo; Wing C Chan; Randy D Gascoyne; Bryan D Young; Louis M Staudt; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 5.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

Review 6.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

7.  Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.

Authors:  Taku Tsukamoto; Miki Kiyota; Eri Kawata; Nobuhiko Uoshima; Shotaro Tatekawa; Yoshiaki Chinen; Hisao Nagoshi; Shinsuke Mizutani; Yuji Shimura; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Shigeo Horiike; Satoru Yasukawa; Akio Yanagisawa; Masafumi Taniwaki; Junya Kuroda
Journal:  Int J Hematol       Date:  2016-12-19       Impact factor: 2.490

8.  Risk Factors of Non-Hodgkin Lymphoma.

Authors:  Yawei Zhang; Ying Dai; Tongzhang Zheng; Shuangge Ma
Journal:  Expert Opin Med Diagn       Date:  2011-11-01

Review 9.  Pathogenesis of follicular lymphoma.

Authors:  Robert Kridel; Laurie H Sehn; Randy D Gascoyne
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

10.  Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.

Authors:  Hongxiu Li; Mark S Kaminski; Yifeng Li; Mehmet Yildiz; Peter Ouillette; Siân Jones; Heather Fox; Kathryn Jacobi; Kamlai Saiya-Cork; Dale Bixby; Daniel Lebovic; Diane Roulston; Kerby Shedden; Michael Sabel; Lawrence Marentette; Vincent Cimmino; Alfred E Chang; Sami N Malek
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.